Lesson of the week: Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin

British Medical Journal

Volumn 329, Issue 7478, 2004, Pages 1333-1335

  Haddow, Alison M ^a   Harris, Dawn ^a   Wilson, Martin ^b   Logie, Hannah ^b  

^a ROYAL CORNHILL HOSPITAL   (United Kingdom)

^b WOODEND HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CIPROFLOXACIN; CLOMIPRAMINE; CREATINE KINASE; PROMAZINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGITATION; ANAMNESIS; BLOOD PRESSURE; CASE REPORT; CONSCIOUSNESS DISORDER; COORDINATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG WITHDRAWAL; FEVER; HUMAN; HYPERREFLEXIA; INFECTION; LEUKOCYTOSIS; MALE; MENTAL DISEASE; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REVIEW; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SHIVERING; SIDE EFFECT; SUBSTANCE ABUSE; SWEAT GLAND DISEASE; TACHYCARDIA; TACHYPNEA; TREMOR; URINARY TRACT INFECTION; URINE INCONTINENCE; ARTICLE; CHEMICALLY INDUCED DISORDER; DEMENTIA; MIDDLE AGED;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; DEMENTIA; FEVER OF UNKNOWN ORIGIN; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 16544389281     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
2. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-71.
3. Ansseau M, Reynolds CF, Kupfer DJ, Pondet PF, Franck G, Dresse AE, et al. Central dopaminergic and noradrenergic blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry 1986;47:320-1.
4. Adnet P, Lesteval P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35.
5. Ames D, Wirshing W. Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome: a possible link? JAMA 1993;269:869.
6. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
7. Lane R, Baldwin D. Selective serotonin reuptake inhibititor: induced serotonin syndrome. J Clin Psychopharmacol 1997;17:208-91.
8. Kontaxakis V, Havaki-Kontaxaki B, Pappa D, Katritsis D, Christodoulou G. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine J Clin Psychopharmacol 2003;23:671-2.
9. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102.
10. Tatsumi M, Groshan K, Blakely R, Richelso E. Pharmacological profile of antidepressant and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58.
11. Kawanshi C. Genetic predisposition to neuroleptic malignant syndrome. Am J Pharmacogenomics 2003;3:89-95.
12. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998;351:1032-3.
13. Spivak B, Maline DI, Kozyrev VN, Mester R, Neduva SA, Ravilov RS, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 2000;15:330-3.
14. Keck PE, Sebastianelli J, Pope HG, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry 1989;50:352-5.
15. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS. A prospective survey of neuroleptic malignant syndrome in a short term psychiatric hospital. Am J Psychiatry 1988;145:4517-8.
16. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H. Risk for definite neuroleptic malignant syndrome. Br J Psychiatry 1992;161:254-7.
17. Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 1994;90:424-6.
18. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9792 Chinese in patients exposed to neuroleptics: a prospective study. Am J Psychiatry 1990;147:1149-55.
19. Information and Statistics Division Common Services Agency. Prescription cost analysis for Scotland. Scotland: ISDCSA, 2004. (Search via www.isdscouand.org.)
20. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.